No abstract available.
Administration, Intravesical* ; Humans ; Reflex, Abnormal*

In clinical settings, intravesical instillation of a drug bolus is often performed for the treatment of bladder diseases. However, it requires repeated instillations to extend drug efficacy, which may result in poor patient compliance. To alleviate this challenge, implantable devices have been developed for the purpose of sustained, intravesical drug delivery. In this review, we briefly summarize the current trend in the development of intravesical drug-delivery devices. We also introduce the most recently developed devices with strong potential for intravesical drug-delivery applications.
Administration, Intravesical ; Drug Delivery Systems ; Patient Compliance ; Urinary Bladder Diseases

No abstract available.
Administration, Intravesical* ; Photochemotherapy* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

No abstract available.
Administration, Intravesical* ; Photochemotherapy* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

Local instillation of Thio-tepa (triethylene thiophosphoramide) is widely used as an important adjunct in the management of papilloma of the bladder. We herein report the 10 case of the bladder cancer administered with Thio-tepa for the treatment and prophylaxis.
Administration, Intravesical* ; Papilloma ; Thiotepa* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

PURPOSE: A prospective study was performed to compare the efficacy and safety of intravesical mitomycin C (MMC) instillation for the prophylaxis of bladder cancer at different concentrations (30 mg or 40 mg). MATERIALS AND METHODS: Ninety-seven patients that received complete transurethral resection for superficial bladder cancer were divided into two-randomized groups. One group (n=53) received 30 mg and the other group (n=44) received 40 mg dose of MMC weekly for 8 weeks, which was followed monthly for 10 months as maintenance therapy. The recurrence rates and side effects in both groups were recorded. The mean follow-up period was 32.4 months in the 30 mg group, and 32.0 months in the 40 mg group. RESULTS: The overall one and two year recurrence rates were 19% and 24% in the 30 mg group, and 12% and 22% in the 40 mg group, which was not significantly different (p>0.05). Most of the side effects were mild and transient. Moreover, the rates of the individual side effects were not statistically different in the two groups. CONCLUSION: Our comparison of 30 mg and 40 mg intravesical MMC instillation showed no difference in either response or side effects. Thus, we tentatively conclude that we can use 30 mg instead of 40 mg as an intravesical MMC instillation dose.
Administration, Intravesical* ; Follow-Up Studies ; Humans ; Mitomycin* ; Prospective Studies* ; Recurrence ; Urinary Bladder Neoplasms* ; Urinary Bladder*

Oxybutynin chloride was administered intravesically in 7 spinal cord injury patients with persistent incontinence and frequent side effects on oral medication. Five mg tablets were dissolved in 20 ml normal saline, and the solution was instilled twice daily and retained for 30 minutes. All patients reported subjective improvement following treatment and all became totally continent. No side effects were observed. In urodynamic study mean bladder capacity increased from 250 to 400ml(P = 0.005) and mean maximum filling pressure decreased from 25 to 18cmH2O (P = 0.283). In conclusion treatment with intravesical oxybutynin chloride can be effective in spinal cord injury patients who either are unresponsive to or have intolerable side effects on oral medication.
Administration, Intravesical ; Humans ; Spinal Cord Injuries* ; Spinal Cord* ; Tablets ; Urinary Bladder ; Urinary Bladder, Neurogenic ; Urodynamics

The effects of intravesical instillation of mitomycin-C(MMC) as inhibitor of development of experimental bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine(BBN) were morphologically studied. BBN was administered for 12 weeks orally and then MMC was instilled intravesically once a week with different concentration of 2 mg/ml and 5 mg/ml and doses of 4 and 8 times. There was a significant reduction in incidence if papilloma in group V which received MMC 2 mg/ml for 8 times and also there were significant reductions in incidence of carcinoma in all MMC treated groups except group III which received MMC 2 mg/ml for 4 times. These results indicate that intravesical instillation of MMC is an effective method to prevent bladder carcinogenesis. The ultrastructural effects of MMC were studied by transmission electron microscope. Partial nucleolar fragmentation and decrease in number and height of the surface microvilli of tumor cells resulting in overall increase in intercellular space and cellular detachment from the tumor surface might have played a role in reduction of cancerincidence.
Administration, Intravesical ; Animals ; Carcinogenesis ; Extracellular Space ; Incidence ; Microvilli ; Mitomycin* ; Papilloma ; Rats* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

The effects of intravesical instillation of mitomycin-C(MMC) as inhibitor of development of experimental bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine(BBN) were morphologically studied. BBN was administered for 12 weeks orally and then MMC was instilled intravesically once a week with different concentration of 2 mg/ml and 5 mg/ml and doses of 4 and 8 times. There was a significant reduction in incidence if papilloma in group V which received MMC 2 mg/ml for 8 times and also there were significant reductions in incidence of carcinoma in all MMC treated groups except group III which received MMC 2 mg/ml for 4 times. These results indicate that intravesical instillation of MMC is an effective method to prevent bladder carcinogenesis. The ultrastructural effects of MMC were studied by transmission electron microscope. Partial nucleolar fragmentation and decrease in number and height of the surface microvilli of tumor cells resulting in overall increase in intercellular space and cellular detachment from the tumor surface might have played a role in reduction of cancerincidence.
Administration, Intravesical ; Animals ; Carcinogenesis ; Extracellular Space ; Incidence ; Microvilli ; Mitomycin* ; Papilloma ; Rats* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

Cells or the monocyte-macrophage lineage are known to exhibit tumoricidal activity following stimulation by BCG, interferon -gamma (INF-gamma) or bacterial products such as lipopolysaccharide(LPS). While the mechanisms involved remain obscure, the generation of reactive nitrogen intermediateds (RNI) by activated macrophage is considered a major participant in mediating the tumoricidal effect. In this study, the authors intended to know the effects of BCG infection on the production and secretion of RNI in the experimental animals. Sprauge-Dawley rats were instillated with BCG intravesically. The production of RNI from peritoneal macrophages and urinary secretion of RNI were measured after intravesical BCG instillation of the rats. The urinary concentration(micrometer/L) of nitrite, stable oxidized form of nitric oxide(N0-), 1 week after intravesical BCG instillation was 20+/-0.5 in the group I (control). 54+/-1.0 in group II (BCG 1x). 63+/-0.5 in group III (BCG 10x) and 17+/-0.5 in group IV (BCG 10x + N(G)MMA). The urinary nitrite concentration(micrometer/L) 3 weeks after intravesical BCG instillation was 17+/-2.0 in group I, 124+/-3.0 in group II, 210+2.5 in group III and 31+/-0.5 in group IV. The production of RNI by peritoneal macrophages 3 weeks after intravesical BCG instillation increased in group III (45+/-2.0 micrometer/L) compared to group I (5+/-1.0 micrometer/L). The peritoneal macrophages treated with LPS and INF-gamma increased nitrite production (36+/-0.5 in group I , 52+/-1.5 micrometer/L in group III). The production of RNI by peritoneal macrophages was inhibited by the treatment of the rats with N(G)MMA (19+/-0.5 in group 1, 17+/-1.5 micrometer/L in group III). The results of this study showed that BCG infection of the rat via intravesical instillation makes the peritoneal macrophages produced RNI and increases the secretion of RNI in the urine. This study suggest that the effects of BCG infection for the treatment of bladder cancer might be mediated by the production or RNI in the tumor bearing host.
Administration, Intravesical ; Animals ; Interferons ; Macrophages ; Macrophages, Peritoneal* ; Mycobacterium bovis* ; Negotiating ; Nitrogen* ; Rats* ; Urinary Bladder Neoplasms